Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
China SXT Pharmaceuticals, Inc. is a specialty pharmaceutical company primarily engaged in the research, development, manufacturing, marketing, and distribution of traditional Chinese medicine (TCM) products, including herbal-based prescription drugs, over-the-counter medicines, and dietary supplements. The company operates within the pharmaceuticals and nutraceuticals industries, with a focus on therapies derived from traditional Chinese medicinal formulations adapted for modern clinical and consumer use.
The company’s core revenue drivers are its portfolio of TCM prescription medicines, OTC products, and herbal dietary supplements, which are sold mainly through hospitals, pharmacies, and distributors in China. China SXT positions itself by combining established TCM formulas with standardized manufacturing and regulatory compliance, seeking to address demand for both conventional and alternative healthcare products. Founded in 1996, the company evolved from a regional TCM producer into a publicly listed entity, completing its U.S. listing through a reverse merger and later trading on NASDAQ under the ticker SXTC.
Business Operations
China SXT Pharmaceuticals conducts operations primarily through its operating subsidiaries, including Shaanxi Xintong Pharmaceutical Research Co., Ltd. and Shaanxi Sanyuan Pharmaceutical Co., Ltd., which manage manufacturing, R&D, and commercial activities. The company generates revenue through the sale of pharmaceutical products manufactured at its GMP-certified facilities, with product categories spanning prescription TCM drugs, OTC medications, and dietary supplements.
Operations are largely domestic, with sales concentrated in the Chinese healthcare system, particularly public hospitals and retail pharmacies. The company controls proprietary product approvals issued by Chinese regulatory authorities and relies on in-house extraction, formulation, and packaging capabilities. Public disclosures reference distribution partnerships within China; however, no material international joint ventures or revenue-generating overseas subsidiaries have been consistently verified in recent public filings.
Strategic Position & Investments
China SXT Pharmaceuticals’ stated strategy centers on expanding its TCM product portfolio, improving manufacturing efficiency, and increasing penetration in higher-margin healthcare channels. Growth initiatives have included investment in new product registrations, upgrading production lines, and selectively entering the health supplement segment to diversify revenue sources beyond prescription drugs.
The company has disclosed periodic capital investments in manufacturing facilities and working capital but has not reported large-scale acquisitions comparable to multinational pharmaceutical peers. Its strategic focus remains on leveraging legacy TCM formulations while adapting them to evolving regulatory standards and consumer preferences. Public filings indicate exploratory interest in biotechnology-enhanced TCM development, though commercialization timelines and outcomes remain uncertain based on available public sources.
Geographic Footprint
China SXT Pharmaceuticals’ operations are headquartered in Shaanxi Province, China, with manufacturing and administrative facilities located within the region. Its commercial footprint is primarily domestic, serving customers across multiple provinces through regional distributors and hospital networks.
While the company is listed in the United States and subject to U.S. SEC reporting requirements, there is no consistent evidence of material revenue derived from North America, Europe, or other international markets. International presence is largely limited to capital markets access and investor relations rather than operational activity.
Leadership & Governance
China SXT Pharmaceuticals is led by an executive team with experience in pharmaceutical manufacturing, TCM research, and corporate management. The company emphasizes operational continuity, regulatory compliance, and disciplined capital management as part of its governance approach.
Key executives include:
- Feng Zhou – Chairman of the Board and Chief Executive Officer
- Ping Guo – Chief Financial Officer
- Zhiming Li – Director
- Jianjun Li – Chief Operating Officer
Leadership disclosures emphasize maintaining product quality standards, expanding approved product offerings, and navigating regulatory and market challenges facing small-cap pharmaceutical manufacturers. Governance practices and executive roles are primarily documented in SEC filings, including Form 10-K and Form 20-F equivalents, though certain biographical details vary slightly across public disclosures, indicating limited transparency typical of micro-cap issuers.